Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-20
2005-12-20
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S411000
Reexamination Certificate
active
06977268
ABSTRACT:
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Importantly, these compounds can be administered orally.
REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3560495 (1971-02-01), Frankus et al.
patent: 3563986 (1971-02-01), Frankus et al.
patent: 3625946 (1971-12-01), Heinrich et al.
patent: 3705162 (1972-12-01), Graudums et al.
patent: 4552888 (1985-11-01), Koppel et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5021404 (1991-06-01), Folkman et al.
patent: 5134127 (1992-07-01), Stella et al.
patent: 5260329 (1993-11-01), Montegilli et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5399363 (1995-03-01), Liversidge et al.
patent: 5405855 (1995-04-01), Andrulis, Jr.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5443824 (1995-08-01), Piacquadio
patent: 5502066 (1996-03-01), Heinemann et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5605684 (1997-02-01), Piacquadio
patent: 5605914 (1997-02-01), Muller
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5643915 (1997-07-01), Andrulis, Jr. et al.
patent: 5654312 (1997-08-01), Andrulis, Jr. et al.
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5731325 (1998-03-01), Andrulis, Jr. et al.
patent: 5798368 (1998-08-01), Muller et al.
patent: 5948403 (1999-09-01), Sone et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6114355 (2000-09-01), D'Amato
patent: 6228879 (2001-05-01), Green et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 1182709 (1970-03-01), None
patent: 0325199 (1989-07-01), None
patent: 768821 (1957-02-01), None
patent: WO 91/10424 (1991-07-01), None
patent: WO 92/14455 (1992-09-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/04533 (1995-02-01), None
patent: WO 00/55134 (2000-09-01), None
Thalidomide: Potential Benefits and Risks,Current Bibliographics in Medicine, pp.: 1-72, Aug. 1, 1997.
Thalidomide in Dermatology and Leprosy,The Lancet, vol./Iss: 2 (8446), pp.: 80-81, Jul. 13, 1985.
Thalidomide Tested for Treatment of AIDS,U.S. Pharmacist, vol./Iss: 18 (8), pp.: 14, Aug. 1993.
Drugs News and Trial Developments,AIDS Patient Care, vol./Iss: 6 (6), pp.: 288, Dec. 1992.
Thalidomide 20 Years On,The Lancet, vol./Iss: II (8245).
Thalidomide,The Merck Index 11th edition, pp.: 1458, 1989.
Algire, G.H. et al., Vascular reactions of normal and malignant tumors in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants,Journal of the National Cancer Institute, vol./Iss: 6, pp.: 73-85, Aug. 1945.
Allegri, A., Confermata I'inefficacia della Talidomide Nella Terapia dei Tumori, Gazzetta Medica Italiana, pp. 124-127, 1964.
Ambs, S., et al., Interactive Effects of Nitric Oxide and the p53 Tumor Suppressor Gene in Carcinogenesis and Tumor Progression,The FASEB Journal, vol./Iss: 11, pp.: 443-448, May 1997.
Apt, W., Effect of Thalidomide on the Course of Experimental Chagas′ Disease,Boletin Chileno de Parasitolgia, vol./Iss: 20 (3), pp. 84-86, Jul. 1965.
Aronson et al., Thalidomide-Induced Peripheral Neuropathy. Effect of Serum Factor on Nerve,Archives of Dermatology, vol./Iss: 120 (11), pp.: 1466-1470, Nov. 1984.
Bach et al., Studies on the Possible Anti-Neoplastic Effect of Thalidomide,ACTA Pathologica Et Microbiologica Scandinavica, vol./Iss: 59, pp.: 491-499, 1963.
Bach et al., Thalidomide in Cancer Chemotherapy,The Lancet, vol./Iss: 1, pp.: 1271, Jun. 8, 1963.
Bahmer, F.A., Therapie bel lymphozytischer Infiltration,Der Hautarzt, vol./Iss: 43, pp.: 663, Oct. 1992.
Bailey, W. et al., Heparin and Basic Fibroblast Growth Factor are Associated with Preservation of Latissimus Cardiomyoplasties in Goats: A Retrospective Study,Journal of Cardiac Surgery, vol./Iss: 11 (4), pp.: 247-255, Jul. 1996.
Balabanova et al., Lupus Erythematosus Hypertrophicus et Profundus,Zeitschrift fur Hautkrankheiten, vol./Iss: 67 (9), pp.: 812-815, Sep. 1992.
Barnes et al., Tumor Necrosis Factor Production in Patients with Leprosy,Infection and Immunity, vol./Iss: 60 (4), pp.: 1441-1446, Apr. 1992.
Barnhill et al., Thalidomide: Use and Possible Mode of Action in Reactional Lepromatous Leprosy and in Various Other Conditions,Journal of the American Academy of Dermatology, vol./Iss: 7 (3), pp.: 317-323, Sep. 1992.
Barnhill, R. et al., Studies on the Anti-Inflammatory Properties of Thalidomide: Effects on Polymorphonuclear Leukocytes and Monocytes,Journal of the American Academy of Dermatology, vol./Iss: 11 (5), pp.: 814-819, Nov. 1984.
Barriere, H., Traitement par la thalidomide,La Presse Medicale, vol./Iss: 12 (15), pp.: 963, Apr. 2, 1983.
Bazzoli et al., The Effects of Thalidomide and Two Analogues on the Regenerating Forelimb of the Newt,Journal of Embyology and Experimental Morphology, vol./Iss: 41, pp.: 125-135, Oct. 1977.
Beccerica, E., L'approccio terapeutico al paziente anziano con artrite reumatoide,La Clinica Terapeutica, vol./Iss: 122, pp.: 289-298, 1987.
Beck, Jr. et al., Vascular Development: Cellular and Molecular Regulation,The FASEB Journal, vol./Iss: 11, pp.: 365-374, Apr. 1997.
Belaube, P. et al., Should Thalidomide be Rehabilitated?,Sem. Hop. Paris, vol./Iss: 59 (45), pp.: 3101-3104, Dec. 8, 1983.
Bensinger, W.I., Supportive Care in Marrow Transplantation,Current Opinion in Oncology, vol./Iss: 4 (4), pp.: 614-623, 1992.
Bernal et al., Cellular Immune Effects of Thalidomide in Actinic Prurigo,International Journal of Dermatology, vol./Iss: 31 (8), pp.: 599-600, Aug. 1992.
Blair, R. et al., Human Mast Cells Stimulate Vascular Tube Formation,The Journal of Clinical Investigation, vol./Iss: 99 (11), pp.: 2691-2700, Jun. 1997.
Blaschke, V. et al., Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere,Arzneimittel Forschung/Drug Research, vol./Iss: 29 (11), pp.: 1640-1642, 1979.
Bonifacino, J. et al., A Peptide Sequence Confers Retention and Rapid Degradation in the Endoplasmic Reticulum,Science, vol./Iss: 2, pp.: 79-80, Jan. 5, 1990.
Bonnetblanc et al., Thalidomide and Recurrent Aphthous Stomatitis,Dermatology, vol./Iss: 193 (4), pp.: 321-323, 1996.
Boodman, S.G., Questions About a Popular Prenatal Test,The Washington Post, Nov. 3, 1992.
Bowers et al., Effect of Thalidomide on Orogenital Ulcers,British Medical Journal, vol./Iss: 287 (6395), pp.: 799-800, Sep. 17, 1983.
Boylen, J.B. et al., Teratogenic Effects of Thalidomide and its Metabolites on the Developing Chick Embryo,Canadian Journal of Biochemistry, vol./Iss: 42, pp.: 35-42, Jan. 1, 1964.
Braun et al., Thalidomide Metabolite Inhibits Tumor Cell Attachment to Concanavalin a Coated Surfaces,Biochemical and Biophysical Research Communications, vol./Iss: 98 (4), pp.: 1029-1034, Feb. 27, 1981.
Brem, H. et al., Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas,Journal of Neurosurgery, vol./Iss: 74, pp.: 441-446, Mar. 1, 1991.
Brent, R. et al., Clinical and Basic Science Lessons from the Thalimode Tragedy: What have we learned about the causes of limb defects?,Teratology, vol./Iss: 38, pp.: 241-251, Jan. 1, 1988.
Bressler, S. et al., Clinicopathologic Correlation of Occult Choroidal Neovascularization in Age-Related Macular Degeneration,Archives of Opthalmology, vol./Iss: 110, pp.: 827, Jun. 1, 1992.
Brodthagen, H., Significant Response of Oral Aphthosis to Thalidomide Treatment,Journal of the American Academy of Dermatology, vol./Iss: 13 (3), pp.: 509, Sep. 1, 1985.
Brovarone, F.V. et al., Occhio e gravidanza,Minerva Ginecologica, vol./Iss: 43, pp.: 141-167, Apr. 1, 1991.
Brown, G.C. et al., Ischaemia and neovascularization,Transactions of the Ophthalmological Societies of the United Kingdom, vol./Iss: C Part III, pp.: 377-380, Sep. 1, 1980.
Br
Children's Medical Center Corporation
Cook Rebecca
Jones Day
LandOfFree
Methods and compositions for inhibition of angiogenesis with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for inhibition of angiogenesis with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibition of angiogenesis with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3495688